Elin Osvik Velle
Overview
Explore the profile of Elin Osvik Velle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
16
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svalastoga M, Larsen T, Brekke J, Enden T, Froen H, Garresori H, et al.
Front Oncol
. 2025 Feb;
15:1520725.
PMID: 39931081
Introduction: It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients. Methods: A analysis of a single-arm interventional clinical trial on apixaban treatment...
2.
Larsen T, Svalastoga M, Brekke J, Enden T, Froen H, Garresori H, et al.
Thromb Res
. 2023 Jun;
228:128-133.
PMID: 37327527
Introduction: In a recent interventional study of cancer patients with newly diagnosed venous thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with therapeutic doses...
3.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Jul;
20(8):1937-1939.
PMID: 35859282
No abstract available.
4.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Feb;
20(5):1166-1181.
PMID: 35114046
Background: There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban...
5.
Hannevik T, Brekke J, Enden T, Froen H, Garresori H, Jacobsen E, et al.
Thromb Res
. 2020 Sep;
196:238-244.
PMID: 32919178
Introduction: The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies indicate that the DOAC apixaban...